Estuardo Aguilar-Cordova Sells 15,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) Stock

Candel Therapeutics, Inc. (NASDAQ:CADL) major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Friday, October 11th. The shares were sold at an average price of $6.05, for a total value of $90,750.00. Following the sale, the insider now directly owns 944,873 shares in the company, valued at $5,716,481.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Estuardo Aguilar-Cordova also recently made the following trade(s):

• On Monday, October 14th, Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock. The stock was sold at an average price of $6.02, for a total value of $90,300.00.
• On Thursday, October 3rd, Estuardo Aguilar-Cordova sold 1,800 shares of Candel Therapeutics stock. The stock was sold at an average price of $6.85, for a total value of $12,330.00.

Candel Therapeutics Stock Up 4.6 %

Shares of Candel Therapeutics stock opened at $6.23 on Thursday. The stock’s fifty day moving average is $6.33 and its 200-day moving average is $6.81. The firm has a market capitalization of $185.23 million, a PE ratio of -4.86 and a beta of -0.95. The company has a quick ratio of 1.62, a current ratio of 1.62 and a debt-to-equity ratio of 1.66. Candel Therapeutics, Inc. has a 12-month low of $0.66 and a 12-month high of $14.30.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. Equities analysts anticipate that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently modified their holdings of CADL. Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at $338,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at $162,000. Rhumbline Advisers acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at $143,000. Finally, Point72 DIFC Ltd acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at $31,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.